Protalix BioTherapeutics
PLX
31 hedge funds and large institutions have $2.45M invested in Protalix BioTherapeutics in 2021 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 7 increasing their positions, 10 reducing their positions, and 11 closing their positions.
3.23% less ownership
Funds ownership: 9.68% → 6.45% (-3.2%)
9% less funds holding
Funds holding: 34 → 31 (-3)
27% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 11
30% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 10
56% less capital invested
Capital invested by funds: $5.61M → $2.45M (-$3.16M)
77% less call options, than puts
Call options by funds: $140K | Put options by funds: $614K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Group One Trading
Chicago,
Illinois
|
+$427K |
| 2 |
SWM
Spire Wealth Management
Mclean,
Virginia
|
+$113K |
| 3 |
Two Sigma Advisers
New York
|
+$89.8K |
| 4 |
Jane Street
New York
|
+$46.8K |
| 5 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
+$42.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$1.04M |
| 2 |
MIH
Meitav Investment House
Bene-Beraq,
Israel
|
-$325K |
| 3 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$241K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$177K |
| 5 |
Walleye Trading
New York
|
-$108K |
PLX Hedge Fund Activity: Q4 2021 in Review
31 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Protalix BioTherapeutics (PLX) for Q4 2021, worth a combined $2.45M — down 56% from $5.61M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of PLX and 8 opened new positions — a net loss of 3 holders — while 10 trimmed existing stakes and 7 added.
The largest buyer was Group One Trading, adding an estimated $427K. The largest seller was Morgan Stanley, cutting an estimated $1.04M.
- 31 institutional investors held Protalix BioTherapeutics (PLX) as of Q4 2021, down from 34 in Q3 2021.
- Funds reported $2.45M of Protalix BioTherapeutics stock for Q4 2021, down 56% quarter-over-quarter.
- 8 funds opened new Protalix BioTherapeutics positions in Q4 2021 and 11 closed out, a net change of -3 holders.
- The largest Protalix BioTherapeutics buyer in Q4 2021 was Group One Trading, an estimated $427K added.
- The largest Protalix BioTherapeutics seller in Q4 2021 was Morgan Stanley, an estimated $1.04M sold.
Based on aggregated 13F filings for Q4 2021.